학술논문
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts
Document Type
article
Author
Talpaz, Moshe; Paquette, Ronald; Afrin, Lawrence; Hamburg, Solomon I; Prchal, Josef T; Jamieson, Katarzyna; Terebelo, Howard R; Ortega, Gregory L; Lyons, Roger M; Tiu, Ramon V; Winton, Elliott F; Natrajan, Kavita; Odenike, Olatoyosi; Claxton, David; Peng, Wei; O’Neill, Peter; Erickson-Viitanen, Susan; Leopold, Lance; Sandor, Victor; Levy, Richard S; Kantarjian, Hagop M; Verstovsek, Srdan
Source
Journal of Hematology & Oncology. 6(1)
Subject
Language
English
Abstract
Abstract Background Ruxolitinib, a Janus kinase 1 and 2 inhibitor, demonstrated improvements in spleen volume, symptoms, and survival over placebo and best available therapy in intermediate-2 or high-risk myelofibrosis patients with baseline platelet counts ≥100 × 109/L in phase III studies. The most common adverse events were dose-dependent anemia and thrombocytopenia, which were anticipated because thrombopoietin and erythropoietin signal through JAK2. These events were manageable, rarely leading to treatment discontinuation. Because approximately one-quarter of MF patients have platelet counts